B2M and lung carcinoma: For the disruption of antigen presentation, acquired homozygous loss of beta-2-microglobulin (B2M) was identified in an acquired ICI-resistant lung cancer sample, which decreased the expression of HLA class I and disrupted the antigen-presentation [68].